Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2008

View Archived Issues

New therapeutic approach against toxoplasmosis reported

MicroRNA mimics suppress Bcr-Abl expression in vitro and in vivo

Phase II trial of Hsp90 inhibitor alvespimycin begins in HER2+ metastatic breast cancer

Data support therapeutic role for buprenorphine in neuropathic pain

Allon initiates phase I clinical trial of AL-108 and AL-208

Three Rivers acquires hepatitis C drug Infergen from Valeant

Vasopressin V2 receptor agonists prepared and tested at Kissei

Roche responds to the results of the IDEAL hepatitis C trial reported

Upstream enters agreement with MSU for drug candidates for tropical parasitic diseases

FDA grants approval to DAKO to market the TOP2A FISH pharmDx breast-cancer test

Gabriel Sciences receives grant from NIH for development of lead antidepressant compound

Alfacell licenses U.S. commercial rights to Onconase to Strativa Pharmaceuticals

Taranabant induces weight loss in obese subjects

Novartis Pharma and Mitsubishi Tanabe revise agreement for Lochol for hypercholesteremia

Genzyme enters license agreement with Moffitt Cancer Center for lung cancer diagnostic

Tolerx receives payment from Genentech following phase Ib clinical study of TRX-1

Anthera reports positive preliminary results from phase IIb clinical trial of A-002

Celsion to proceed with phase II pivotal breast cancer trial

Protox Therapeutics commences phase IIa PRX-302 trial in prostate cancer

Summit's lead drug candidate, SMT-D001, enters phase II clinical trials

Recent patents describe novel analgesic agents

Remicade label enhancement receives E.U. approval in Crohn's disease

E.U. marketing authorization granted for GSK's Avamys for allergic rhinitis therapy

E.C. grants Remicade label enhancement for ankylosing spondylitis and psoriatic arthritis

New oncolytic drugs described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...